Best Life Sciences Companies in South Carolina, United States
The 90 best Life Sciences companies in South Carolina, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bridge to Life.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in South Carolina
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Bridge to Life Provider of cold storage solutions for the preservation of organ transplants | $57M | 22 mo ago | 29 | — | WordPressMySQLPHP+27 | — | — |
| 2 | Nubad Nucleic acid-based drug discovery company developing RNA and DNA-targeted therapeutics | $25M | 14 mo ago | — | Dev Arya Founder | — | 6 patents Patents concentrated in chemistry & materials | — |
| 3 | Cogentix Medical Minimally invasive treatment of voiding dysfunctions and endoscopy solution | $25M | 117 mo ago | 141 | — | — | — | — |
| 4 | Elastrin Developer of therapeutic targets related to arterial and lung diseases | $17M | 21 mo ago | 10 | — | — | — | — |
| 5 | SynAgile Specialty company focused on developing therapeutics for Parkinson's disease | $16M | 105 mo ago | 13 | Ephraim Heller Co-Founder & CEO | — | 62 patents Continuous intraoral drug delivery devices and extrusion systems for sustained oral dosing | — |
| 6 | GlucoTec Glycemic management system | $16M | 155 mo ago | — | Trefor Thomas President and CEO | — | — | — |
| 7 | Senex Biotechnology Developing cancer therapeutics, targeting drug resistance and metastasis for incurable cancers | $10M | 45 mo ago | 6 | Igor Roninson Founder and President | — | 77 patents CDK8/19 small‑molecule inhibitors and degraders for oncology and cytokine‑storm therapy | — |
| 8 | Zyl Therapeutics Developer of hydrogel-derived nanoparticle system for topical applications 19Funding top 35%Talent top 35%Global bottom 29%Market bottom 21% All 4 signals ▾Fundingtop 35% Talenttop 35% Globalbottom 29% Marketbottom 21% Funding: Raised $9.4M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Talent: Analyst team rating 5/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 19/100 | $9M | 16 mo ago | 7 | Scott Pancoast CEO and Founder (and Board Member) | — | — | — |
| 9 | HS Pharmaceuticals Silicate-based molecules that facilitate the body’s immune system to attack cancerous cells while also… | $9M | 207 mo ago | 9 | — | — | 437 patents Small-molecule immunomodulators targeting CXCR4/CXCR2, BTK, IL-6 and complement pathways. | — |
| 10 | Expanse Bio Developer of ex vivo systems for long-term ovarian assessment | $8M | 9 mo ago | — | Bradley Weegman CEO | — | — | — |
| 11 | Blinktbi Innovating neurological disease management with non-invasive blink reflex technology | $7M | 35 mo ago | 8 | Ryan Fiorini Co-Founder & COO | — | 14 patents Wearable ocular blink detection and monitoring for neurological and headache disorder diagnostics | — |
| 12 | LoxiGen Developer of inhibitors of lysyl oxidases to target extracellular matrix remodeling in various therapeutic… | $6M | 10 mo ago | — | Ozgur Sahin Founder | — | — | — |
| 13 | IMCS Manufacturer of genetically modified enzymes products | $5M | 57 mo ago | 27 | Qian Wang Co-Founder | — | — | 2 launchs |
| 14 | Purilogics Innovative membrane technology for biopharma, enabling faster, cost-effective biologics purification | $5M | 58 mo ago | 8 | Jinxiang Zhou Director of Purilogics | — | 6 patents Nucleic‑acid affinity chromatography membranes for oligonucleotide purification | 1 launch |
| 15 | Natalist Provider of at-home health tests and virtual care and treatment options | $5M | 80 mo ago | 8 | Linh Trinh CEO | Cart FunctionalityShopifyBugHerd+19 | — | — |
| 16 | CreatiVasc Develops and commercializes vascular technology-based medical devices for end stage renal diseases | $5M | 154 mo ago | 5 | Steve Johnson ex-President & CEO | — | — | — |
| 17 | Orbis Health Solutions Developer of therapeutic vaccines for cancer | $5M | 56 mo ago | — | Thomas Wagner Founder & CEO | — | 124 patents Tumor cell isolation platforms and nucleic‑acid vaccine delivery systems for cancer immunotherapy | — |
| 18 | CuRE Innovations Specialty company developing and marketing oral health products | $4M | 123 mo ago | 2 | — | — | — | — |
| 19 | International BioMedical Devices Continuous Thermal Capsulotomy system for cataract surgery | $4M | 117 mo ago | — | Steve Bryant President & CEO | — | — | — |
| 20 | ARCpoint Labs Provider of genetic testing services | $3M | 15 mo ago | 322 | — | WordPressMySQLPHP+25 | — | — |
| 21 | AcePre Developer of therapeutics and health resources focused on disease management | $3M | 21 mo ago | 7 | Daping Fan Founder | — | — | — |
| 22 | Avancen Provider of medication management devices for hospitals and patients | $2M | 167 mo ago | 12 | Steve Seide Chief Executive Officer | — | 3 patents Disposable incontinence garments and on-demand oral medication dispensing systems. | — |
| 23 | Valeant Dermtology A product for dermatitis and wound care from Valeant Dermatology | $2M | 180 mo ago | 89 | — | — | — | — |
| 24 | Immunologix Produce antibody-based therapeutics for different biological target | $2M | 179 mo ago | 42 | Douglas Carnes Founder and CEO | — | — | — |
| 25 | MitoChem Therapeutics Developer of therapies for diseases causing mitochondrial dysfunction | $2M | 46 mo ago | 5 | Barbel Rohrer Co-Founder | — | — | — |
| 26 | Circa Bioscience Provider of diagnosis for neurodevelopmental and metabolic diseases | $1M | 33 mo ago | — | Kevin Champaigne Founder | — | — | — |
| 27 | Selah Genomics Molecular Diagnostics for Drug Discovery and Clinical Applications. | $900K | 123 mo ago | 11 | — | — | — | — |
| 28 | GlycoPath Developer of glycan assays for biomarker discovery | $876K | 33 mo ago | 2 | Kathy Phlegar CEO | — | — | — |
| 29 | Lydex pharma Developer of small molecule drug therapy for ischemia-reperfusion | $645K | 58 mo ago | — | C. James Chou Co-Founder | — | — | — |
| 30 | Moterum Technologies Developer of devices to aid the recovery of neurological or nerve functions | $550K | 107 mo ago | 16 | David Huizenga Founder & CEO | — | — | — |
| 31 | iDTx Systems Aerosol medication dispenser for patients on ventilation | $455K | 140 mo ago | — | Pearce Gilbert CEO | — | — | — |
| 32 | Aptus Bioreactors Bioreactor systems for tissue-engineered heart valves and cardiovascular research | $322K | 9 mo ago | 2 | — | — | — | — |
| 33 | Lucie Medical Developer of medical devices improving maternal health outcomes | $309K | 21 mo ago | — | Jennifer West Co-Founder & CEO | — | — | — |
| 34 | DPX Technologies Developer of tools for chromatography by using patented pipette tip technology | $255K | 62 mo ago | 19 | William Brewer President and CEO | WordPressMySQLPHP+29 | 12 patents Patents concentrated in transport & manufacturing processes | 1 launch |
| 35 | ToleRaM Nanotech Nano particle drug delivery platform | $225K | 93 mo ago | — | Nadig Satish Co-Founder & CMO | — | — | — |
| 36 | MxBiodevices Injectable nanoscaffold for the treatment of diabetic foot ulcers (DFU’s) and other chronic wounds | $210K | 148 mo ago | — | Marilyn Thompson Co-Founder & CFO | — | — | — |
| 37 | SealCath Innovative medical device supplier improving colorectal procedure efficiency and patient care | $207K | 95 mo ago | — | Cephus E Simmons Founder & CEO | — | — | — |
| 38 | Avallano Developer of clinical research platform for clinical trial patient engagement | $200K | 64 mo ago | 7 | Paul Maggiora Co-Founder & CEO | — | — | — |
| 39 | CharlestonPharma Developing anti-nucleolin antibodies for broad-spectrum cancer therapy | $200K | 162 mo ago | — | Brad Goodwin Founder & CEO | — | 6 patents Therapeutic antibodies and agents targeting nucleolin for cancer and disease treatment | — |
| 40 | Viradys Waste management solution provider | $125K | 123 mo ago | 3 | Michael Green President and CEO | — | — | — |
| 41 | Cirtemo Optical filter manufacturer specializing in multivariate optical elements for spectral analysis | $100K | 105 mo ago | 3 | — | — | — | — |
| 42 | Rhythmlink Provider of brain health medical devices | — | 39 mo ago | 78 | Shawn Regan Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+29 | 9 patents MRI‑compatible EEG electrodes, rapid‑apply caps, and skin‑friendly monitoring cables. | 1 job opening |
| 43 | PCT Developer of disinfectant and cleaning solutions for hospitals | — | 54 mo ago | — | Bayan Giltsoff Co-Founder | — | 4 patents IoT-based material tracking and adaptive device polling for supply chain management | — |
Top 12 Life Sciences companies in South Carolina
#1
Funding Raised · North Charleston, South Carolina · founded 2022$7.6Mraised▾
Developer of ex vivo systems for long-term ovarian assessment. The company focuses on creating an ex vivo system for the assessment of ovarian damage at morphological, functional, and molecular levels in a whole ovary model.
- Aug 2025Grant (prize money)$309.3K
- Oct 2023Grant (prize money)$2.5M
- Sep 2023Grant (prize money)$309.3K
- Aug 2019Grant (prize money)$2M
#2
Funding Raised · Greenville, South Carolina · founded 2009$25Mraised▾
Nucleic acid-based drug discovery company developing RNA and DNA-targeted therapeutics. We identify therapeutic agents targeting nucleic acids, developing novel probes, assays, and small molecule therapeutics for RNA and DNA structures in human disease. Our technologies assist in discovering RNA and DNA-targeted small molecule drugs. We seek academic and private partners for collaborative opportunities to expand our technology. We are a B2B tech company focused on drug discovery, offering products and services in the pharmaceutical industry. Our work has a social impact by targeting diseases through innovative therapeutic approaches.
- Apr 2025Grant (prize money)$521K
- Mar 2025Grant (prize money)$3M
- Jan 2025Grant (prize money)$3.2M
- 2022Grant (prize money)$4.1M
#3
Funding Raised · Charleston, South Carolina · founded 2020$6.3Mraised▾
Developer of inhibitors of lysyl oxidases to target extracellular matrix remodeling in various therapeutic areas. It offers a lead compound the orally bioavailable LOX inhibitor LXG6403 which overcomes chemotherapy resistance in several chemoresistant in vitro, organoid, and in vivo models of highly aggressive triple negative breast cancer.
- Aug 2025Grant (prize money)$2.5M
- Mar 2025Grant (prize money)$2.5M
- Jun 2023Grant (prize money)$1.4M
#4
Series A · Columbia, South Carolina · founded 2012 · 29 employees$57Mraised▾
Provider of cold storage solutions for the preservation of organ transplants. The product catalog includes Belzer UW-cold storage solution, Belzer MPS UW-machine perfusion solution, sodium chloride solution for sterile slush, and Frech-sized cannulas and tubing.
- Aug 2024Series A$1M
- Aug 2021Series A$56M
- Aug 2021Conventional Debt—
#5
Series B · Greenville, South Carolina · founded 2017 · 7 employees$9.4Mraised▾
Developer of hydrogel-derived nanoparticle system for topical applications. The company has developed a patented drug delivery system Nanopods, a hydrogel-derived nanoparticle system. The system can be used to deliver payloads such as nitric oxide, curcumin, cannabis, siRNA, iron, and melanin topically.
- Jan 2025Grant (prize money)$263.2K
- May 2023Grant (prize money)$294K
- Sep 2022Grant (prize money)$263K
- Jun 2022Series B$5.2M
#6
Series A · Simpsonville, South Carolina · founded 2017 · 10 employees$16.8Mraised▾
Developer of therapeutic targets related to arterial and lung diseases. The company has built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that thickens the arteries and manages drugs' targets.
- Sep 2024Series A$500K
- Oct 2023Series A$4.8M
- Aug 2023Series A$2M
- Mar 2022Series A$10M
#7
Public · Greenville, South Carolina · founded 2005 · 322 employees$3.5Mraised▾
ARCpoint Labs provides genetic testing services. The company offers genetic tests for paternity, background screening, drug testing services for businesses and individual. Their range of tests also includes federally mandated and DOT testing.
- Mar 2025Post IPO$800K
- Jan 2025Post IPO$554.5K
- Jul 2024Post IPO$1M
- Jan 2024Post IPO$1.1M
#8
Funding Raised · Columbia, South Carolina · founded 2017 · 7 employees$3Mraised▾
Developer of therapeutics and health resources focused on disease management. The company formulates natural compounds as health-promoting supplements and disease-modifying drugs. It also develops biotechnology-based therapies for conditions including cancer, cardiovascular disease, Alzheimer's, and sepsis. The company provides health education information to the public.
- Sep 2024Grant (prize money)$300K
- Sep 2024Grant (prize money)$499.4K
- Jun 2023Grant (prize money)$597.3K
- Sep 2022Grant (prize money)$299.6K
#9
Funding Raised · Clemson, South Carolina · founded 2013 · 2 employees$321.7Kraised▾
Bioreactor systems for tissue-engineered heart valves and cardiovascular research. They provide innovative bioreactor systems and accessories for creating and testing living, patient-specific tissue-engineered heart valves, aiming for "One Surgery, for Life." Their technology supports preconditioning valve scaffolds, preclinical testing, and cardiovascular implant testing, potentially replacing animal models. They offer rotating cell seeders for location-specific cell seeding, vascular bioreactors for tunable cardiovascular conditions, and quick connect fittings for simplified connections. MechAnnulus valve mounts secure heart valves during conditioning, while compliance and burst pressure modules determine tissue mechanical properties. They are focused on regenerative medicine, cardiovascular equipment, and consulting services to develop and test living tissue replacements and other medical devices. Their solutions are customized to meet researcher's needs and allow testing and growing all types, shapes, and sizes of heart valves.
- Aug 2025Grant (prize money)$321.7K
#10
Series A · Charleston, South Carolina · founded 2017 · 8 employees$6.9Mraised▾
Innovating neurological disease management with non-invasive blink reflex technology. They are a biotech company pioneering blink reflex technology intended to improve the detection and management of neurological disease and conditions. Their FDA-cleared EyeStat device offers a rapid, objective assessment of neurological function through the blink reflex. This technology enables earlier detection, personalized care, and improved patient outcomes. The i-blink app extends its reach to clinical and telehealth settings, facilitating low-cost, objective blink capturing for enhanced neurological management. They collaborate with pharmaceutical and academic partners to improve diagnosis and clinical trials and empower patients with remote monitoring tools. Their technology provides researchers and doctors insights into neurological activity following a head injury. The company's cloud-based platform ensures secure data management and comprehensive reporting, supporting better decision-making in neurology.
- Jul 2023Series A$1.6M
- Feb 2021Series A$6M
- Nov 2018Conventional Debt$673.4K
- Oct 2017Seed$850K
#11
Funding Raised · Spartanburg, South Carolina · founded 2023$308.5Kraised▾
Developer of medical devices improving maternal health outcomes. The company focuses on addressing critical issues in maternal healthcare, specifically aiming to reduce complications and improve the overall experience for women giving birth. Its team possesses extensive experience in medical device development, clinical applications, regulatory compliance, and commercialization. The company's efforts contribute to a safer and more effective birthing process.
- Sep 2024Grant (prize money)$308.5K
#12
Seed · Columbia, South Carolina · founded 2002 · 6 employees$10.3Mraised▾
Developing cancer therapeutics, targeting drug resistance and metastasis for incurable cancers. The company is a drug discovery and development company focused on creating cancer therapeutics. Their lead program targets a protein crucial for cancer cell adaptation, which leads to drug resistance and metastasis. They are developing selective small-molecule inhibitors for prostate cancer, breast cancer, and leukemia. The company is also exploring the use of these inhibitors in combination therapies for various cancers, as well as for inflammation, cardiovascular, and other diseases. They are also developing drugs aimed at other unique cancer targets. This is a B2B model, focused on pharmaceutical research and development, with a social impact of making cancers curable.
- Sep 2022Grant (prize money)$400K
- Sep 2017Grant (prize money)$299.2K
- Sep 2015Grant (prize money)$2M
- Sep 2013Seed$426.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.